Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments

Area of Science:

• Virology
• Oncology
• Immunology

Background:

• Epstein-Barr Virus (EBV) is the first identified human oncogenic virus, infecting over 90% of the global population.
• While most EBV infections are asymptomatic, EBV is implicated in the development of cancers and autoimmune diseases.
• EBV is associated with numerous human neoplasms, including Hodgkin's lymphoma (HL), non-Hodgkin's lymphoma (NHL), nasopharyngeal carcinoma (NPC), and gastric carcinoma (GC).

Purpose of the Study:

• To review experimental and clinical advancements in understanding EBV's role in oncogenesis.
• To focus on EBV-associated lymphoproliferative disorders.
• To highlight progress in diagnostics and targeted therapies for EBV-related malignancies.

Main Methods:

• Comprehensive literature review of experimental and clinical studies on EBV.
• Analysis of EBV's viral proteins and miRNAs in cellular transformation.
• Examination of EBV's association with various cancers and lymphoproliferative disorders.

Main Results:

• EBV encodes proteins and miRNAs that facilitate persistent infection and cell transformation.
• EBV is demonstrably linked to the pathogenesis of several cancers and lymphoproliferative disorders.
• The precise mechanisms of EBV-driven oncogenesis are still under investigation.

Conclusions:

• EBV plays a significant role in the development of specific human cancers, particularly lymphoproliferative disorders.
• Ongoing research into EBV's oncogenic potential is crucial for understanding disease mechanisms.
• Emerging diagnostic tools and targeted therapies offer promising avenues for managing EBV-related malignancies.